From Nasdaq: 2025-02-14 17:10:04

IGC Pharma, Inc. (IGC) reported a quarterly loss of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.03. This marks an improvement from the loss of $0.09 per share a year ago, showing an earnings surprise of 33.33%. The company has exceeded EPS estimates twice in the last four quarters.

In the same quarter, IGC Pharma, Inc. generated revenues of $0.26 million, surpassing the Zacks Consensus Estimate by 28.50%. This compares to $0.2 million in revenues from the previous year. The company has also beaten revenue estimates two times in the last four quarters. Despite a 9% decline in shares since the beginning of the year, the future stock performance will be influenced by management’s earnings call commentary.

As investors speculate on the next moves for IGC Pharma, Inc., the key indicator to watch is the company’s earnings outlook. The current consensus EPS estimate for the upcoming quarter is -$0.03, with revenues projected to reach $0.3 million. The Zacks Rank #3 (Hold) suggests the stock is expected to perform in line with the market in the near future. Another company in the same industry, United Therapeutics (UTHR), is set to release its quarterly earnings report with an expected EPS of $6.23 and revenues of $725.32 million.

For investors considering IGC Pharma, Inc., understanding the latest stock movements and earnings estimates revisions is crucial. The Zacks Rank system has proven effective in analyzing these trends. With a focus on the industry performance, Medical – Drugs currently ranks in the top 35% of Zacks industries, indicating potential growth opportunities. To explore the best stocks to buy for the next 30 days, investors can access the free report from Zacks Investment Research.



Read more at Nasdaq: IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates